{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:22:17Z","timestamp":1792639337458,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.cca.2013.12.036","type":"journal-article","created":{"date-parts":[[2014,1,9]],"date-time":"2014-01-09T19:47:18Z","timestamp":1389296838000},"page":"86-91","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Serum HER2 supports HER2-testing in tissue at the time of primary diagnosis of breast cancer"],"prefix":"10.1016","volume":"430","author":[{"given":"Dorit","family":"Di Gioia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Dresse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Mayr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothea","family":"Nagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Heinemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Kahlert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Stieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2013.12.036_bb0005","first-page":"2605","article-title":"Is circulating HER-2 more than just a tumor marker?","volume":"7","author":"Baselga","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cca.2013.12.036_bb0010","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1200\/JCO.2001.19.8.2334","article-title":"When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer","volume":"19","author":"Yamauchi","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cca.2013.12.036_bb0015","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.cca.2013.12.036_bb0020","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1373\/49.10.1579","article-title":"Potential clinical utility of serum HER-2\/neu oncoprotein concentrations in patients with breast cancer","volume":"49","author":"Carney","year":"2003","journal-title":"Clin Chem"},{"key":"10.1016\/j.cca.2013.12.036_bb0025","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3816\/CBC.2004.n.014","article-title":"Monitoring the circulating levels of the HER2\/neu oncoprotein in breast cancer","volume":"5","author":"Carney","year":"2004","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.cca.2013.12.036_bb0030","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000218029","article-title":"Serum levels of C-erbB-2 (HER-2\/neu) in patients with malignant and non-malignant diseases","volume":"18","author":"Molina","year":"1997","journal-title":"Tumour Biol"},{"key":"10.1016\/j.cca.2013.12.036_bb0035","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1200\/JCO.2011.35.0868","article-title":"Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31","volume":"29","author":"Perez","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cca.2013.12.036_bb0040","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cca.2013.12.036_bb0045","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/172460089901400103","article-title":"c-erbB-2 in serum of patients with breast cancer","volume":"14","author":"Harris","year":"1999","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.cca.2013.12.036_bb0050","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/JCO.1997.15.7.2518","article-title":"Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2\/c-neu protein","volume":"15","author":"Yamauchi","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cca.2013.12.036_bb0055","first-page":"1","article-title":"Serum HER-2 predicts response and resistance to trastuzumab treatment in breast cancer","author":"Petersen","year":"2013","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.cca.2013.12.036_bb0060","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/cncr.23689","article-title":"Serum HER-2\/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer","volume":"113","author":"Ali","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.cca.2013.12.036_bb0065","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.2005.03.4744","article-title":"HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial","volume":"24","author":"Perez","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cca.2013.12.036_bb0070","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1158\/1055-9965.667.13.4","article-title":"Loss of antigenicity in stored sections of breast cancer tissue microarrays","volume":"13","author":"Fergenbaum","year":"2004","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.cca.2013.12.036_bb0075","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1200\/JCO.2008.17.3989","article-title":"Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients","volume":"27","author":"Leary","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cca.2013.12.036_bb0080","first-page":"4423","article-title":"High levels of serum HER-2\/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer","volume":"9","author":"Jensen","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cca.2013.12.036_bb0085","first-page":"3075","article-title":"Hormonal treatment with sex steroids in women is associated with lower p105 serum concentrations","volume":"17","author":"Meden","year":"1997","journal-title":"Anticancer Res"},{"key":"10.1016\/j.cca.2013.12.036_bb0090","first-page":"51","article-title":"Serum levels of the c-erbB-2 (HER2\/neu) encoded oncoprotein fragment p105 in normal pregnancies","volume":"11","author":"Meden","year":"1997","journal-title":"In Vivo"},{"key":"10.1016\/j.cca.2013.12.036_bb0095","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/annonc\/mdh266","article-title":"Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer","volume":"15","author":"Di Cosimo","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cca.2013.12.036_bb0100","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/BF01806813","article-title":"Prognostic significance of serum c-erbB-2 protein in breast cancer patients","volume":"40","author":"Willsher","year":"1996","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.cca.2013.12.036_bb0105","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1023\/A:1006033214721","article-title":"ErbB-2 protein in sera and tumors of breast cancer patients","volume":"49","author":"Breuer","year":"1998","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.cca.2013.12.036_bb0110","first-page":"1433","article-title":"Tissue expression and serum levels of the oncoprotein HER-2\/neu in 157 primary breast tumours","volume":"25","author":"Pallud","year":"2005","journal-title":"Anticancer Res"},{"key":"10.1016\/j.cca.2013.12.036_bb0115","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/ijc.22166","article-title":"Serum c-erbB-2 protein is a useful marker for monitoring tumor recurrence of the breast","volume":"120","author":"Imoto","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cca.2013.12.036_bb0120","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1023\/A:1005734429304","article-title":"c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value","volume":"51","author":"Molina","year":"1998","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.cca.2013.12.036_bb0125","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/annonc\/mdm585","article-title":"Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival","volume":"19","author":"Ludovini","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cca.2013.12.036_bb0130","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1136\/jcp.2005.029603","article-title":"Serum HER-2 concentration in patients with primary breast cancer","volume":"59","author":"Kong","year":"2006","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.cca.2013.12.036_bb0135","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1200\/JCO.20.6.1467","article-title":"Elevated serum Her-2\/neu level predicts decreased response to hormone therapy in metastatic breast cancer","volume":"20","author":"Lipton","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cca.2013.12.036_bb0140","first-page":"2703","article-title":"Circulating HER-2\/erbB-2\/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662","volume":"7","author":"Hayes","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cca.2013.12.036_bb0145","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1373\/clinchem.2006.067512","article-title":"Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer","volume":"52","author":"Kong","year":"2006","journal-title":"Clin Chem"},{"key":"10.1016\/j.cca.2013.12.036_bb0150","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/clinchem\/48.8.1314","article-title":"Relationship of serum HER-2\/neu and serum CA 15-3 in patients with metastatic breast cancer","volume":"48","author":"Ali","year":"2002","journal-title":"Clin Chem"},{"key":"10.1016\/j.cca.2013.12.036_bb0155","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/172460080101600406","article-title":"Evaluation of HER-2\/neu in serum and tissue of primary and metastatic breast cancer patients using an automated enzyme immunoassay","volume":"16","author":"Dittadi","year":"2001","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.cca.2013.12.036_bb0160","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s13277-010-0025-9","article-title":"Evaluation of tumor markers (HER-2\/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value","volume":"31","author":"Molina","year":"2010","journal-title":"Tumour Biol"},{"key":"10.1016\/j.cca.2013.12.036_bb0165","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00432-011-1095-9","article-title":"High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients","volume":"138","author":"Kong","year":"2012","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.cca.2013.12.036_bb0170","first-page":"1196","article-title":"Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells","volume":"59","author":"Codony-Servat","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.cca.2013.12.036_bb0175","first-page":"1043","article-title":"Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer","volume":"23","author":"Molina","year":"2003","journal-title":"Anticancer Res"},{"key":"10.1016\/j.cca.2013.12.036_bb0180","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1515\/cclm.2011.822","article-title":"Circulating levels of HER-2\/neu oncoprotein in breast cancer","volume":"50","author":"Molina","year":"2012","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.cca.2013.12.036_bb0185","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1515\/CCLM.2009.241","article-title":"Serum HER-2 concentrations for monitoring women with breast cancer in a routine oncology setting","volume":"47","author":"Sorensen","year":"2009","journal-title":"Clin Chem Lab Med"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898113005317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898113005317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T18:16:14Z","timestamp":1688926574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898113005317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":37,"alternative-id":["S0009898113005317"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2013.12.036","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}